Human umbilical vein endothelial cells (HUVEC) in culture express two classes of binding sites for tissue-type plasminogen activator (t-PA). The high-affinity binding site has been identified as PA inhibitor type 1 (PAI-1), which binds t o the catalytic portion of the molecule, while the second site binds t-PA through an active-site independent domain. Because recombinant t-PA (rt-PA) is often administered concomitantly with heparin, we investigated the effects of heparin on rt-PA binding t o HUVEC. Preincubation of HUVEC with heparin at 4°C increased the binding of radiolabeled rt-PA in a time-and dose-dependent manner. One-half maximal increase in binding was observed within 10 minutes of heparin addition. When HUVEC were preincubated with optimal concentrations (5 U/mL) of heparin for 4 hours at 4"C, a 2.5-2 0.2-fold increase in specific binding was observed (mean f SEM, n = 12, P < .01). Other highly sulfated glycosaminoglycans and fucoidan (a sulfated polymer of fucose) stimulated rt-PA binding as well, whereas glycosaminogly-EGULATION of plasminogen activator (PA) activity R is required for the orderly development and dissolution of fibrin clots and other biologic processes, including cell motility and proliferation.' The mechanism by which PAS are activated or inhibited in plasma has been described in considerable detail, but the extent to which the regulation may differ when these same processes occur on cell surfaces or in extracellular matrix has received less study.
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The binding of plasminogen2x3 as well as tissue-type PA (t-PA)4-6 or urokinase-type PA ( U -P A )~,~ to endothelial cell receptors may accelerate the rate of plasmin f0rmation~2~98 and decrease the rate constants for their interaction with or2-antiplasmin3 and or2-macroglobulin9 and, to a lesser extent, with PA inhibitors, including PA inhibitor type 1 (PAI-1).lo The biochemical transition of PAI-1 from the "active" to the "latent" state is slowed when the inhibitor is bound to vitronectin in the plasma or within the matri~.Il-'~ cans with lower sulfate content than heparin did not. Several results suggested that heparin increased the binding of rt-PA t o "cell-associated PAI-1. First, only active-site-dependent binding was enhanced by heparin, whereas binding of activesite blocked rt-PA was not affected. Second, extracts from HUVEC preincubated with heparin contained increased amounts of rt-PA-PAL1 complexes as shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Third, antibodies t o PAI-1 blocked the increased binding entirely. HUVEC preincubated with heparin also bound increased amounts of enzymatically active radiolabeled urokinase-type PAS. However, HUVEC preincubated with heparin did not express increased amounts of immunoreactive PAI-1. Therefore, heparin, at therapeutic concentrations, may enhance or stabilize the association of PAS with endothelial cellassociated PAI-1. 0 1992 by The American Society of Hematology.
The net result of these interactions is to modulate the site and extent of plasmin production. In turn, plasmin is involved in matrix remodeling both directly by the degradation of noncollagenous elements and indirectly through the activation of procollagena~e.~~ Therefore, regulation of the PA system by components of the matrix may influence its own composition and integrity as well as modulate the rate or extent of plasmin-mediated cell migration through these structures.
Although the concentration of PAI-1 in normal plasma is less than 30 ng/mL, a plasma concentration of recombinant t-PA (rt-PA) greater than 500 ng/mL is generally required for successful clinical thromb01ysis.l~ This observation suggests that the concentration of inhibitors, such as PAI-1, may greatly exceed normal plasma concentrations at the sites of vascular disease and thrombosis. Both activated platelets16 and subendothelial cell matrix" may serve as sources of PAI-1 at sites of vascular injury and plaque rupture. In addition, endothelial cells, which produce large amounts of PAI-1 in vitro6J7Js and display a large surface area in vivo, may also contribute to the disposition of rt-PA, particularly at sites of injury or disease where matrix is exposed or synthesis is increased.
Endothelial cells may also modulate PAI-1 activity. Heparan sulfate, which regulates the activity of vitronectin, is a major component of the extracellular matrix of endothelial cells, and anionic glycosaminoglycans (GAGS), including heparin and related compounds, modify the activity of both plasminogen a c t i v a t o r~l~-~~ and inhibitor^.^^,^' In addition, heparin binds reversibly to endothelial cells in v i t r~~,~~ and possibly in vivo. Some of these interactions may become important clinically when heparin and rt-PA are administered concurrently. Therefore, we sought to determine whether heparin or related compounds modulate the interaction of rt-PA with endothelial cell-associated PAI-1 or other cellular binding sites.
HEPARIN ENHANCES T-PA BINDING TO HUVEC
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MATERIALS AND METHODS
GAGs.
Porcine mucosal heparin (166 U/mg), bovine lung heparin (152.5 U/mg), ovine mucosal heparin (182 U/mg), bovine kidney heparan sulfate, bovine trachea chondroitin sulfate A, porcine skin chondroitin sulfate B, shark cartilage chondroitin sulfate C, dextran sulfate (molecular weight S,OOO), fucoidan, hyaluronic acid, bovine corneal keratin sulfate, and pentosan polysulfate were all purchased from Sigma (St Louis, MO). Human umbilical vein endothelial cells (HUVEC) were preincubated with each GAG at a concentration of 30 pg/mL, unless otherwise specified. For most studies, unless otherwise noted, porcine mucosal heparin was used, for which 30 pg/mL is equivalent to 5 U/mL.
Monoclonal antibody (MoAb) to PAI-1 was obtained from Monozyme (Lyngby, Denmark). Polyclonal rabbit antihuman PAL1 and anti-PAI-2 antisera were the kind gifts of Dr T.C. Wun (Monsanto Corp, Chesterfield, MO). Polyclonal IgG anti-protease nexin-1 (PN-1) antibody was generously supplied by Dr D.J. Knauer (University of California,
The control MoAb used was anti-Leu-3a (Becton Dickinson, Mountain View, CA). Normal rabbit serum and rabbit IgG were also used as controls.6
Cells. Confluent monolayers of HUVEC (passages 2 through 6) were grown in fibronectin-coated 96-well microtiter plate wells in the absence of heparin using Medium 199 (GIBCO BRL, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (Flow Laboratories, McLean, VA), penicillin-streptomycin (GIBCO BRL), and endothelial cell growth factor, as described.6
Two sources of wild-type rt-PA were used, one kindly provided by Genentech (South San Francisco, CA) and one from the Genetics Institute (Cambridge Park, MA). Both preparations are predominantly (> 90%) singlechain t-PA and have essentially identical binding characteristics to HUVEC.6 Variant rt-PA missing the finger fibronectin and epidermal growth factor domains (AFE-rt-PA) was the generous gift of Dr Glenn Larsen (Genetics I n~t i t u t e ) .~~
The wild-type and variant rt-PAS were expressed in CHO cells and purified using erythrina trypsin inhibitor-Sepharose (ETI-Sepharo~e).~~ This variant and wild-type rt-PA had comparable catalytic activities (403 v 442 U/pg, respectively), determined using a colorimetric substrate assay method.31 Protein concentrations were determined using the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Richmond, CA), or by absorbance at 280 nm. Catalytic site-blocked rt-PA was prepared by adding diisopropylfluorophosphate (DFP; Sigma) to each protein two times for 30 minutes each at 22°C (20 mmol/L, final concentration). Catalytic site-blocked rt-PA (DIP-rt-PA) and AFE-rt-PA (DIP-AFE-rt-PA) contained less than 1% of the PA activity of the parent molecule. Recombinant PAL1 (rPAI-1) was expressed in yeast and purified as previously de~cribed.3~ rPAI-1 was reactivated by adding 4 mol/L guanidine-HC1 (Schwarz/ Mann, Cleveland, OH) for 1 hour at 37°C,34 followed by desalting using a PD-10 column (Pharmacia LKB Biotechnology, Inc, Piscataway, NJ).
Purified PAS were radiolabeled with NalZ5I using Iodo-Beads (Pierce Chemical Co, Rockford, IL) for 5 to 10 minutes at 22"C.6,8 Unbound radioactive iodine was removed using a PD-10 column preequilibrated with a buffer containing 0.5 mol/L potassium phosphate, pH 7.2, and 0.01% Triton X-100. The proteins were labeled to a specific activity of 0.2 to 5.0 x lo6 cpm/pg. lZ5I rt-PAs retained approximately 50% of the amidolytic activity of the unlabeled material. Wild-type rt-PA and AFE-rt-PA were metabolically labeled with [35S]-methionine to a specific activity of 1 to 6 x lo6 cpm/pg and were isolated using ETISepharose?' Both [35S]-labeled rt-PAs retained 100% of the PA
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activity of the unlabeled protein.31 Radioiodinated u-PAS generally retained greater than 90% of the PA activity of the unlabeled material. Each radiolabeled ligand was diluted in Dulbecco's phosphate-buffered saline supplemented with calcium and magnesium (GIBCO BRL) with 3 mg/mL bovine serum albumin (PBS-BSA) before measuring binding to HUVEC.
Monolayers of H W E C were cooled to 4°C and washed twice with PBS-BSA. The cells were then incubated at 4°C for 0 to 4 hours in PBS-BSA containing various concentrations of heparin or other GAGs and washed two more times. The binding of radiolabeled rt-PA (9 to 18 nmol/L, unless otherwise noted) to HUVEC was then determined as previously described.6 Briefly, cells were incubated with radiolabeled rt-PA for 2 hours at 4°C with and without a 50-fold molar excess of unlabeled rt-PA, and then washed four times. After visual inspection of the monolayers, the contents of the wells were removed using 1 N NaOH or trypsin-EDTA (GIBCO BRL) at 37°C and radioactivity was counted. The final volume for binding reactions was 50 pL with 25,000 cellslwell. Therefore, 1 nmol/L cell-bound rt-PA is equivalent to approximately 91 ng rt-PA/million cells or 1.0 x 106 molecules of rt-PA/cell. Each experimental point was performed in at. least duplicate wells. Fold increase in binding is defined as the ratio of the amount of ligand specifically bound to cells preincubated with heparin divided by the amount specifically bound in the absence of heparin. In general, approximately 50% to 70% of the total binding was specific, without any consistent effect (up or down) of heparin on the degree of nonspecific binding. A two-tailed paired t-test was used for statistical analysis with a P value of <.OS considered significant.
To visualize the effect of heparin preincubation, binding of rt-PA was allowed to reach equilibrium. The contents of replicate wells were analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE, 10%) under reducing conditions using the method of Laemmli35 followed by autoradiography. To assess the possible contribution of lysine binding sites, HUVEC were preincubated for 30 minutes at 4°C with PBS-BSA containing epsilon amino caproic acid (EACA Sigma) (10 mmol/L final concentration). In other samples, the EACA was added after preincubation with heparin, but before the addition of rt-PA.2 For experiments evaluating the effects of specific antibodies on rt-PA binding, HUVEC were preincubated with 5 U/mL heparin, washed twice with PBS-BSA, and 30 p L of antisera or buffer was added to the wells for 1 hour at 4°C. The cells were incubated with 30 p L radiolabeled rt-PA for an additional 2 hours and specific binding was determined.
To assess whether heparin affected the binding of other PAS that also interact with PAI-1, we performed similar binding experiments using several forms of radiolabeled u-PA. We used (1) a single-chain form of u-PA (scu-PA kind gift of Dr Jack Henkin, Abbott Laboratories, Chicago, IL), which has no detectable PA activity and does not form complexes with PAI-1, but that binds with high affinity to cellular receptors expressed on a variety of cell types, including HUVEC; (2) high molecular weight two-chain u-PA (tcu-PA, Calbiochem, San Diego, CA), which both binds to u-PA receptors and forms complexes with PAI-18; and (3) low molecular weight u-PA (LMW-u-PA Calbiochem), which is formed by removal of the epidermal growth factor and kringle domains by proteolytic cleavage. LMW-u-PA retains an intact serine protease domain and can interact with PAI-1, but does not bind to u-PA receptors. Binding studies were performed using radiolabeled ligand (9 to 18 nmol/L) in the presence and absence of 50-fold molar excess unlabeled ligand to determine specific binding. HUVEC were preincubated with media containing heparin (50 U/mL) or control media without heparin for 2 hours at 4°C and specific binding Binding of rt-PA to HUVEC.
Binding of u-PAS to HUVEC.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From determined in the same manner as described for rt-PA. Less than 10% of the specific binding of radiolabeled scu-PA to wells with H W E C could be attributable to binding to plastic, as judged by the degree of specific binding of the same ligand to wells treated with fibronectin and complete medium, but without cells.
The expression of PAI-1, PAI-2, and PN-1 antigen on HUVEC was measured using a solid-phase radioimmunoassay as previously described.36 Briefly, confluent monolayers of H W E C were cooled to 4"C, washed, and preincubated with heparin (5 U/mL) in PBS-BSA or with PBS-BSA alone for 4 hours at 4°C. The cells were washed two times with Hanks Balanced Salt Solution (Gibco BRL) containing 1% BSA (HBSS-BSA) and then incubated sequentially with the respective primary antibodies and either 1251-labeled goat antimouse IgG (New England Nuclear, Boston, MA) to detect the MoAbs, or 1251-labeled staphylococcus protein A (Behring Diagnostics, San Diego, CA) to detect the rabbit antibodies, and the cell-associated radioactivity determined.36
The activity of PAI-1 in the presence and absence of heparin was measured using a modification of the method of Verheijen?' rt-PA (0.22 ng [lo0 m u ] to 2.2 ng (1, OOO mu]) were added to empty wells. Reactivated (or latent) PAL1 (10 ng), heparin (5 U/mL), or both were added and the residual rt-PA activity was measured after the addition of plasminogen, S-2251, and cyanogen bromide-generated fibrin(ogen) fragments:* as described.6 Activity was expressed as the change in absorbance divided by the square of time (AA/t2)?7.39 In other experiments, wells were pretreated with fibronectin and incubated with complete medium with or without H W E C overnight until confluent monolayers were observed. HUVEC were then incubated with and without heparin (5 U/mL) for 4 hours at 4°C as above. After two washes, 0.5 to 4 ng of rt-PA in PBS-BSA was added both to wells with and without H W E C in a volume of 50 pL. Both sets of wells were incubated for an additional 30 minutes at 37°C. Plasminogen (0.13 pmol/L final concentration) and S-2251 (0.6 mmol/L final concentration) diluted in 0.1 mol/L Tris HCI with 0.1% Tween 80, pH 7.5, were added. Fibrin(ogen) fragments (120 pg/mL final c o n c e n t r a t i~n )~~ were added to some wells at this time as well, and the final volume was adjusted to equal 250 pL with buffer. The change in absorbance over time was then measured in a microtiter plate reader (Dynatech Laboratories, Chantilly, VA).
Measurement of PAIS on HUVEC.
Effects of PAI-1 and heparin on rt-PA activi@
RESULTS
Previous studies from several laboratories indicate that rt-PA can bind irreversibly and with high affinity to PAI-1 associated with endothelial cells and their surrounding
In addition, HUVEC may express additional, lower-affinity sites not involving PAI-1 !,6, 41 We first investigated whether preincubating HUVEC with heparin altered the binding of rt-PA to either site. In the first two sets of experiments, lZ5I rt-PA was added at a concentration (9 nmol/L) at which binding to cell-associated PAI-1 via the catalytic site would be predicted to predominate.6 HUVEC were preincubated with heparin (5 U/mL) at 4°C for various periods of time, unbound heparin was removed, and the binding of lZ5I rt-PA at equilibrium was determined (Fig  1) . Heparin augmented the binding of rt-PA at all times tested. The predominant effect was observed with preincubation times as short as 5 minutes. However, binding of rt-PA continued to increase, reaching a maximum with 2 hours of preincubation. No substantial change in binding was measured after an additional 2 hours of preincubation. All further studies (unless otherwise noted) were performed with 4 hours of incubation.
Augmentation of rt-PA binding varied with the concentration of heparin added. An increase in rt-PA binding was observed at heparin concentrations as low as 0.08 U/mL (Fig 2) . The maximal effect was seen when heparin was added at concentrations of approximately 0.5 U/mL, and no further increment was seen when heparin was added at concentrations as high as 50 U/mL. Under optimal conditions (5 U/mL for 4 hours), rt-PA binding to HUVEC preincubated with heparin increased 2.5--C 0.2-fold (n = 12, kSEM,P < .01). For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
We next addressed whether heparin increased the binding of t-PA to the high-affinity sites (eg, PAI-1) or to the lower-affinity, nonactive site-dependent sites reported by several group^.^-^ To only study the effect of heparin on nonactive site-dependent binding, we assessed the amount of specific binding of 'ZI-DIP-rt-PA (90 nmol/L) to HU-VEC in the presence and absence of heparin pretreatment, No increase in binding was observed (Fig 2) . To study the effect of heparin on active site-dependent binding alone, we measured specific binding to HUVEC using various concentrations of lEI-rt-PA in the presence of an excess of 50-fold molar unlabeled DIP-rt-PA (Fig 3) . A saturable amount of binding was present both in the presence and absence of heparin, with an increase in binding in the heparin pretreated cells at all concentrations of added rt-PA. Finally, the increase in rt-PA binding to HUVEC by heparin was unaffected by EACA (10 mmol/L), which has been shown to inhibit lysine-dependent binding of plasminogen via its kringle domains to endothelial c e k 2
The stimulatory effect of heparin on the binding of rt-PA to HUVEC was also seen when heparin and rt-PA were added to the HUVEC simultaneously. Stimulation was most pronounced at clinically relevant concentrations (ie, I 10 U/mL) (Fig 4) . At higher concentration, the binding of rt-PA to HUVEC was inhibited.
The data presented above suggested that PAI-1 might be involved in the heparin-induced binding of rt-PA to HUVEC. Several additional experiments were performed to explore this possibility further. We studied the effect of heparin on the binding of a variant rt-PA molecule that is missing the finger and growth factor domains (AFE-rt-PA), but retains Heparin stimulates rt-PA binding to PAI-1. catalytic activity equivalent to the wild-type (WT-rt-PA) molecule.31 This variant molecule, and other similar domain deletion variants424 have a prolonged plasma residence time in vivo, thought to be secondary to an inability to bind to cells via the putative t-PA recept0r.4~ Preincubation of HUVEC with heparin increased the binding of 35S-metlabeled AFE-rt-PA and WT-rt-PA 2.7-? 0.6-and 2.7-f 0.5-fold, respectively (n = 5). In contrast, DIP-AFE-rt-PA showed no specific binding to HUVEC in the presence or absence of heparin, confirming the absolute requirement for an intact catalytic site for binding of this variant to these cells.
These studies indicate that heparin stimulates the binding of rt-PA to HUVEC through its active site, possibly to PAI-1. Heparin could augment such an interaction by inducing the production or expression of additional PAI-1 molecules, slowing the conversion of PAI-1 to its latent form, or by changing the affinity of rt-PA for PAI-1 or the affinity of rt-PA/PAI-1 complexes for the cell and/or matrix. To distinguish among these possibilities, three additional sets of experiments were performed.
First, preincubation of HUVEC with heparin under the same conditions that augmented binding of rt-PA did not increase the binding of antibodies to PAI-1 (or PAI-2 or PN-1) (Table 1) . Second, HUVEC were preincubated with heparin and the binding of 1251-rt-PA was measured in the (Table 2) . In contrast, anti-PN-1 antibodies did not significantly block the heparin effect. Third, at the completion of the equilibrium binding experiments, HUVEC were solubilized and the mobility of the cell-associated radiolabeled rt-PA was assessed using SDS-PAGE. An increase in the formation of an SDS-stable, radiolabeled band with an apparent molecular mass of approximately 105 Kd, consistent with the migration of rt-PA-PAI-1 complexes, was evident in cells preincubated with heparin (Fig 5, lane 2) compared with control cells (lane 1). Incubation with excess unlabeled rt-PA blocked the formation of these complexes completely (lanes 3 and 4) .
Effect of heparin on the binding of u-PA to HIICIEC. To determine whether the effect of heparin on HUVEC was specific for t-PA, we measured its effect on the binding of LMW-u-PA (which binds only through its catalytic site), xu-PA (which binds only to receptor), and tcu-PA (which binds by both mechanisms).x Preincubation of HUVEC with heparin stimulated the specific binding of radiolabeled LMW-u-PA 1.82-fold (mean, n = 2). Similarly, heparin stimulated the specific binding of tcu-PA 1.6-2 0.3-fold (n = 3), but did not stimulate the binding of tcu-PA that had been inactivated by DIP (fold increase, 0.99 [mean] ; n = 2). The binding of radiolabeled scu-PA, which is not enzymatically active, was increased minimally by heparin (fold increase, 1.22 [mean]; n = 2).
Effect of heparin on HVEC-associated PA inhibitoty acriviq. We had previously observed that rt-PA added to HUVEC at low concentrations formed rt-PA-PAI-I complexes devoid of PA activity, whereas rt-PA added at higher concentrations retained activity? Therefore, we examined whether preincubation of HUVEC with heparin altered their capacity to modulate t-PA activity at physiologic concentrations of t-PA. We used an indirect assay of t-PA activity by measuring the amount of plasmin generated after adding known quantities of t-PA, plasminogen, and a chromogenic plasmin substrate. The concentration of rt-PA when initially exposed to the cells ranged from 10 to 80 ng/mLwith the final concentration range of rt-PA after the addition of plasminogen and Chromogenic substrate of 2 to 16 ng/mL. In the absence of cells, a linear dose response was noted both in the presence and absence of fibrin(ogen) fragments (Fig 6) . When the same amount of t-PA was added to wells with HUVEC, we observed a decreased amount of plasmin generated in the presence or absence of fibrin(ogen) fragments, consistent with the expression of PAI-1 activity on the cell surface. Thus, at physiologic concentrations of t-PA, exposure of t-PA to HUVEC results in slower plasmin generation. Preincubation of HUVEC with heparin (5 U/mL for 4 hours) had no effect on PA inhibitory activity measured in the presence of fibrin, suggesting no net effect on plasmin generation. In the absence of fibrin, HUVEC preincubated with heparin expressed slightly more PA inhibitor activity than did control cells, although these differences did not reach statistical significance (Fig 6B) . Nevertheless, no increase in t-PA activity was observed in heparin-pretreated HUVEC.
This finding appeared to be in contrast to previously published work on the effect of heparin on t-PA-mediated plasminogen activation?y We therefore tested the effect of heparin on the interaction of the same reagents (rt-PA, plasminogen, and S-2251) in the presence and absence of purified reactivated recombinant PAI-1. In the absence of cells or purified PAI-1, heparin stimulated the PA activity of rt-PA (200 to 600 mu) (Fig 7, open presence of heparin (dark circles) also inhibited plasmin generation, although the absolute values for plasmin activity were higher than in the absence of heparin. In other studies, heparin neither reactivated latent soluble PAI-1 directly, nor changed the extent or duration of its activation by guanidine (data not shown). Our results suggest that, although heparin may in some fashion "activate" rt-PA, the presence of both PAI-1 and plasminogen as potential substrates for rt-PA in an assay dependent on plasmin generation may cause one to detect relatively decreased plasmin activity values due to rapid increased rt-PA/PAI-1 complex formation. As can be seen by comparing the plasmin generated by rt-PA alone (Fig 7, open squares) with the amount generated by the same concentrations of rt-PA in the presence of both heparin and PAI-1 (Fig 7,  dark circles) , the net effect can be an increase, decrease, or no change, depending on the concentrations of the reactants. We conclude from these studies that, although heparin may lead to increased t-PA-mediated plasmin generation in the fluid phase using purified systems, heparin pretreatment of HUVEC does not stimulate net t-PA-mediated plasmin generation at physiologic concentrations of t-PA due to interaction with cell-or matrixassociated PAI-1.
We tested several fractions of heparin as well as other GAGs for their effect on rt-PA binding. Heparins derived from several species of animals had a comparable effect, as did higher and lower molecular weight fractions of heparin (Table 3) . Moreover, no difference was observed between the anticoagulant fraction of heparin that bound to antithrombin I11 (AT-111) sepharose and the nonanticoagulant fraction. Dextran sulfate and pentosan polysulfate stimulated rt-PA binding to an extent comparable to that of unfractionated heparin. Fucoidan, a sulfated polymer of fucose, produced the greatest augmentation, causing rt-PA binding to increase more than fourfold. Chondroitin sulfates A, B, and C, hyaluronic acid, keratin sulfate, and heparan sulfate, all
Effect of other GAGs andfractions of heparin.
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of which have little or no sulfate content, had little or no effect on rt-PA binding (Table 3) . Thus, this effect of heparin can be mimicked by other GAGs, and might be related to their sulfate content or charge density.
DISCUSSION
Recent studies indicate that the efficacy of rt-PA after coronary artery thrombosis is improved by subsequent administration of heparin, presumably by blocking thrombin and factor Xa-mediated procoagulant a c t i~i t y .~~,~~ However, administration of heparin before rt-PA therapy for acute myocardial infarction has not been shown to improve arterial patency at 90 minutes.47 This result was surprising, because heparin enhances the fibrinolytic activity of both rt-PA and u-PA in v i t r~. l~-~~ However, most of these studies have been performed using purified proteins or fibrin clots. Fibrinolytic reactions in vivo are also modulated by cell surfaces, such as the endothelium, that have the capacity to bind both heparin28,2y and PAS.^-^ Because thrombosis in the clinical setting is generally a focal disorder, the effect of heparin on fibrinolytic activity at sites of vascular disease may contribute to or detract from its effectiveness.
Heparin affects several steps in the fibrinolytic system. Heparin augments synthesis of rt-PA by lung fibroblasts stimulated with ECGF48 and stimulates PA activity mediated by t-PA20,4y and u-PA21J4,4y within minutes after addition in vitro or in vivo.50-53 A similar effect has been noted when other highly charged polyanions have been studied.54 There is also extensive evidence to suggest that heparin enhances the fibrinolytic activity of rt-PA in purified ~ystems.5~ Certain fractions of heparins6 bind both to plasminogen and to the finger and, to a lesser extent, the K2 domain of rt-PA,3y,57 thereby forming a ternary complex which increases the kat for plasminogen activation 25-fold.25 Low-density lipoprotein and lipoprotein (a) inhibit this stimulatory effect of heparin.2S Complexes between heparin and the catalytic chains of rt-PA and plasmin have been reported as well.S8
In most of these studies, the effect of heparin has been examined in the absence of plasma or a source of PA inhibit0r.5~ In plasma, addition of heparin has been reported to inhibit the development of u-PA activity generated from SCU-PA.~~ Indeed, heparin had little effect on the rate of clot dissolution when administered concurrently with rt-PA in some experimental systems.w.61 These latter results suggest that heparin may also have an effect on the interaction of PAS with their major plasma inhiditor, PAI-1. Edelberg et al have shown that in purified systems, heparin enhances the rate of inhibition of t-PA by PAI-1 with a fourfold increase in the second-order rate constant.27
Our studies show that heparin augments the binding of rt-PA to HUVEC. Enhancement of binding was observed at concentrations of both heparin and rt-PA used in the clinical management of thrombosis. Several lines of evidence suggest that the increase in rt-PA binding occurs because heparin facilitates an interaction between the catalytic site of rt-PA and PAI-1 on the endothelial cell surface or in the matrix where it remains accessible to the enzyme.* The effect of heparin was fully evident when a variant protein lacking the finger and epidermal growth factor domains, but having an intact catalytic site, was analyzed. Heparin did not stimulate the binding of rt-PA or the AFE-rt-PA variant after their catalytic sites had been blocked. These data suggest that neither the finger nor epidermal growth factor domains are required for heparin to augment rt-PA binding. Moreover, heparin stimulated formation of cell-associated rt-PA-PAI-1 complexes, while antibodies to PAI-1 blocked the ability of heparin to augment rt-PA binding. Finally, heparin also stimulated the binding of LMW-u-PA and tcu-PA, but not the binding of scu-PA, consistent with involvement of the catalytic portion of the serine protease molecule in the process.
The mechanism by which heparin augments rt-PA or u-PA binding to PAI-1 is unclear. Any hypothesis must take into consideration the following experimental observations. First, the time course of the heparin effect is consistent with the kinetics of its binding to the endothelium.28r2y The major effect of heparin was detectable within minutes after addition, but maximal augmentation required incubation with the endothelium for 2 hours. Second, the activity of heparin appeared to depend on its sulfate content or net charge, but was not dependent on its anticoagulant activity or average molecular weight. In addition, other highly sulfated GAGs or sulfated polymers, such as fucoidan, also stimulated rt-PA binding, while GAGs with lesser degrees of sulfate, such as heparan sulfate, were inactive. Third, the effect of heparin, although absolutely dependent on the presence of PAI-1, did not increase the amount of PAI-1 antigen expressed on or under the cells. This argues against exposure of matrS2 or induction of protein synthesis by heparin. Fourth, heparin neither reactivated soluble PAI-1 nor caused it to remain in its active form. Fifth, heparin did For personal use only. on November 11, 2017. by guest www.bloodjournal.org From not inhibit rt-PA activity directly. Rather, as reported by others, the amidolytic activity of soluble rt-PA was augmented by heparinSS and this augmentation could be inhibited by recombinant PAI-1.
The mechanism by which heparin increases the interaction of rt-PA with PAI-1 is uncertain. Heparin may cause a conformational change in or around the catalytic site of rt-PA that both enhances its proteolytic activity and renders this site more accessible to PAI-1. This would explain why heparin does not increase the apparent PA activity of "cell-associated" rt-PA measured by an increase in plasmin activity (Fig 6) . Rather, activation of rt-PA in the presence of a source of unbound PAI-1, such as may occur at the site of thrombosis, may accelerate the formation of inactive complexes at the expense of forming more plasmin.
The observation that heparin stimulates the binding of rt-PA and tcu-PA comparably may indicate that the conformation and/or activity of cell-or matrix-associated PAI-1 is altered directly, Heparin may permit additional ionic bridges to be formed between PAI-1 and either PA or it may stabilize existing bonds between the molecules.63 It has been hypothesized that the paucity of cysteines in PAI-1 capable of stabilizing its three-dimensional structure may permit internal rearrangements as a consequence of changes in ionic environment, such as would be likely to occur when heparin or other polyanions are present.@ This latter explanation for our results would also be consistent with the recent work by Edelberg et al, who reported a fourfold increase in the inhibition constant of PAI-1 for t-PA in the presence of he~arin.2~ However, we cannot exclude the possibility that heparin independently facilitates the binding of both PAI-1 and rt-PA to the cell surface or the cellular matrix, raising the concentration of each reactant and thereby accelerating the formation of complexes.
There are several other possible explanations for our observations. First, in the absence of heparin, only a portion of native PAI-1 associated with HUVEC may be recognized by rt-PA. PAI-1 associated with HUVEC may exist in several conformations that are recognized differently by various probes. Russell et a1 reported that a catalytically inactive rt-PA variant in which the catalytic site serine was replaced with an alanine retained its ability to bind to endothelial cell-associated PAI-l,65 although the molecule was no longer able either to cleave PAI-1 nor release rt-PA-PAI-1 complexes into the media. Binding of this variant rt-PA to HUVEC-associated PAI-1 greatly exceeded the binding of wild-type rt-PA.65 Heparin may induce a conformation change in wild-type rt-PA having similar consequences, thereby enabling it to bind cellassociated PAI-1 molecules not recognized by the parent molecule (Fig 3) . Second, our results could be explained by the formation of ternary complexes between rt-PA, PAI-1, and cell-or matrix-bound heparin that slows the dissociation of complex from the cell surface. Third, our data do not exclude the possibility that heparin may also change the activity of PAI-1 indirectly through the known interaction of both molecules with ~i t r o n e c t i n .~~.~~ Cultured HUVEC express approximately 0.02 pg of active PAI-1 per cell. Assuming the vasculature of an adult contains approximately 1012 endothelial then approximately 20 mg of active PAI-1 would be exposed on the surface of endothelial cells in vivo if they expressed as much PAI-1 as HUVEC. While this is unlikely, binding of rt-PA to the endothelium and other cellular sources of PAI-1 contained in thrombi may help to explain why plasma concentrations ofrt-PA that are 10-to 100-fold higher than the plasma concentrations of PAI-1 must be attained before fibrinolysis is achieved. Therefore, even a small increase in the PA inhibitory capacity of PAI-1 caused by heparin could have a sigdificant impact on the effective concentration of PA at sites where matrix is exposed or PAI-1 synthesis is increased. Vergnes et a1 recently found that in patients treated for 60 days with standard heparin without rt-PA treatment, there was no change in global fibrinolytic activity in plasma as measured by the euglobulin clot lysis However, they measured a small but significant increase in PAI-1 activity, with a rather large increase in both total t-PA and t-PA/PAI-1 complex antigen levels detected by immunoassay.
We do not know whether the apparent inefficacy of heparin to augment lysis of coronary occlusions results in any way from its effect on PAI-1 activity measured in vitro in this study. However, our findings are in accord with the increasing body of evidence that the enzymatic steps involved in fibrinolysis, like the reactions that promote coagulation, may be accelerated or decelerated on cell surfaces. Our data suggest that the GAG composition of the matrix surrounding the endothelium may contribute to the regulation of the enzymatic activity of t-PA and, hence, the fibrinolytic cascade. Localized changes in the matrix composition at discrete sites in the vasculature may alter the fibrinolytic balance and contribute to the development of thrombosis or the resistance to thrombolysis. 
